SUPPLEMENT 1. SUPPLEMENTARY DATA TO:
Timur Syunyakov, Maxim Sharaev, Victor Savilov, Olga Karpenko,
Marat Kurmyshev, Vyacheslav Yarkin, Vadim Ushakov, Alexander Bibyaev,
Kristina Soloviova, Alisa Andruschenko.

A comparison of regional brain volumes in older adults with and without
history of COVID-19.
Consortium Psychiatricum 2022; published online December 2021.
DOI: 10.17816/CP145.

This appendix is a part of the original submission.
The appendix is posted as it was supplied by the authors.
EXCLUSION CRITERIA:

1. Diagnosis of dementia
2. Diagnosed stroke within 2 years prior to study inclusion (excluding transient dynamic cerebral circulation disorders)
3. Established diagnoses of Parkinson's disease, Huntington's disease
4. Established history of depression or anxiety disorder under 45 years of age + current (treatment and hospitalization)
5. Current comorbid diagnosis of severe (regardless of psychotic symptoms) depressive, anxiety, or phobic disorder
6. Current acute or severe chronic somatic or infectious disease
7. Comorbid psychotic disorders with a history or current
8. Diagnosis of bipolar disorder, current or history
9. Having a contraindication for MRI
10. Taking vasoactive or nootropic drugs (excluding drugs from the acetylcholinesterase inhibitor group and NMDA-receptor antagonists) less than 2 months before inclusion in the study
11. Taking the following drugs within 1 week prior to screening and visit 1:
   (a) Acetylcholinesterase inhibitors
   (b) Memantine
   (c) Tricyclic and heterocyclic antidepressants (clomipramine, amitriptyline, imipramine, mianserine)
   (d) Paroxetine, venlafaxine except when taken more than 1 year before inclusion
   (e) Antidepressants with strong sedative effects (mirtazapine, trazodone)
   (f) Antipsychotics
   (g) Choline blockers
   (h) First-generation antihistamines, including hydroxyzine, diphenhydramine
   (i) Barbiturate-containing medications (Corvalol, Valokordin, Valoserdin)
   (j) Benzodiazepines
   (k) Zolpidem, zopiclone, eszopiclone
   (l) Topiramate, phenytoin, carbamazepine, oxcarbazepine, gabapentinoids (pregabalin, gabapentin)
   (m) Opioid-containing analgesics
   (n) Antibiotics and antibacterials with bacteriostatic action (e.g., macrolides, aminoglycosides, fluoroquinolones)
   (o) Oral antifungal preparations
   (p) Antiviral drugs (ribavirin and antiretrovirals)
   (q) Reserpine
   (r) Baclofen
   (s) Cytostatics
   (t) Oral glucocorticoids
   (u) Indomethacin
   (v) Methylprednisolone
   (w) Dipyridamole
Informed consent of patients (for research articles and reviews of clinical cases)